Pharma Equity Group A/S (CPH:PEG)

Market Cap	138.71M -37.4%
Revenue (ttm)	n/a
Net Income	-21.02M
EPS	-0.02
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,655
Average Volume	262,142
Open	0.1135
Previous Close	0.1130
Day's Range	0.1000 - 0.1135
52-Week Range	0.0706 - 0.1580
Beta	1.01
RSI	56.44
Earnings Date	Mar 18, 2026

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG